Literature DB >> 29959764

Prospective Series of Nine Long Noncoding RNAs Associated with Survival of Patients with Glioblastoma.

Bingxi Lei1,2, Lei Yu1, Thapa Ashish Jung2, Yuefei Deng2, Wei Xiang1, Yawei Liu1, Songtao Qi1.   

Abstract

OBJECTIVE: To analyze the long noncoding RNA (lncRNA) expression profile of glioblastoma multiforme (GBM) and identify prognosis-related lncRNAs, as well as their related protein-coding genes and functions.
METHOD: The lncRNA expression profiles were obtained by microarray in six samples each of GBM and normal brain tissue. The lncRNAs expressed were significantly different between the two groups and used to detect their associations with patient survival time by downloading the related data from The Cancer Genome Atlas (TCGA). The total RNA-sequencing data of 152 patients diagnosed GBM level 3 with complete clinic information was downloaded. The survival time-dependent lncRNAs were identified by multivariate Cox regression analysis. For the survival time-dependent lncRNAs, we used the Pearson correlation coefficient and z test to search their associated protein-coding genes downloaded from TCGA. Functions of these genes were annotated by the Database for Annotation, Visualization, and Integrated Discovery (DAVID) for gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis.
RESULTS: More than 1,000 antisense lncRNAs and enhancer lncRNAs were selected for analysis in this study. Data from 152 cases with RNA-seq of GBM level 3 with complete information on GBM were downloaded from the TCGA database. Univariate Cox regression analysis revealed 19 lncRNAs with survival time dependency. These nine lncRNAs were used to construct our survival model via multivariate Cox regression analysis: TP73-AS1, AC078883.3, RP11-944L7.4, HAR1B, RP4-635E18.7, HOTAIR, SAPCD1-AS1, AC104653.1, and RP5-1172N10.2. The nine lncRNAs associated with them were inputted into the DAVID database for gene ontology and KEGG function enrichment analysis. The result showed these genes were enriched with ion binding, transport, cell-cell signaling, plasma membrane parts, and more, and they were mainly related to neuroactive ligand-receptor interaction pathway, calcium signaling pathway, and the mitogen-activated protein kinase signaling pathway.
CONCLUSION: The nine lncRNAs were a set of biomarkers for the prognosis of patients with GBM, enabling a more accurate prediction of survival and revealing more biological functions. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29959764     DOI: 10.1055/s-0038-1655549

Source DB:  PubMed          Journal:  J Neurol Surg A Cent Eur Neurosurg        ISSN: 2193-6315            Impact factor:   1.268


  5 in total

1.  The lncRNA Punisher Regulates Apoptosis and Mitochondrial Homeostasis of Vascular Smooth Muscle Cells via Targeting miR-664a-5p and OPA1.

Authors:  Yanyan Yang; Min Li; Yan Liu; Zhibin Wang; Xiuxiu Fu; Xingqiang He; Qi Wang; Xiao-Xin Li; Huibo Ma; Kun Wang; Lu Zou; Jian-Xun Wang; Tao Yu
Journal:  Oxid Med Cell Longev       Date:  2022-05-25       Impact factor: 7.310

2.  CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment.

Authors:  Xiudong Guan; Yangyang Wang; Yueqian Sun; Chuanbao Zhang; Shunchang Ma; Dainan Zhang; Deling Li; Wang Jia
Journal:  J Inflamm Res       Date:  2021-12-23

3.  Pyroptosis-Related lncRNAs Predict the Prognosis and Immune Response in Patients With Breast Cancer.

Authors:  Xia Yang; Xin Weng; Yajie Yang; ZhiNong Jiang
Journal:  Front Genet       Date:  2022-03-14       Impact factor: 4.599

Review 4.  Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.

Authors:  Christopher Chin; Emma S Lunking; Macarena de la Fuente; Nagi G Ayad
Journal:  Front Oncol       Date:  2018-11-13       Impact factor: 6.244

5.  An eight-mRNA signature outperforms the lncRNA-based signature in predicting prognosis of patients with glioblastoma.

Authors:  Zhenyu Gong; Fan Hong; Hongxiang Wang; Xu Zhang; Juxiang Chen
Journal:  BMC Med Genet       Date:  2020-03-19       Impact factor: 2.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.